MX2023003855A - Metodos para reducir la expresion de apociii. - Google Patents

Metodos para reducir la expresion de apociii.

Info

Publication number
MX2023003855A
MX2023003855A MX2023003855A MX2023003855A MX2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A
Authority
MX
Mexico
Prior art keywords
methods
fcs
reducing apociii
shtg
fpl
Prior art date
Application number
MX2023003855A
Other languages
English (en)
Spanish (es)
Inventor
Veronica J Alexander
Sotirios Tsimikas
Stanley T Crooke
Richard S Geary
Brett P Monia
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of MX2023003855A publication Critical patent/MX2023003855A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2023003855A 2020-10-02 2021-09-24 Metodos para reducir la expresion de apociii. MX2023003855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087095P 2020-10-02 2020-10-02
PCT/US2021/052001 WO2022072244A1 (en) 2020-10-02 2021-09-24 Methods for reducing apociii expression

Publications (1)

Publication Number Publication Date
MX2023003855A true MX2023003855A (es) 2023-04-14

Family

ID=80950871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003855A MX2023003855A (es) 2020-10-02 2021-09-24 Metodos para reducir la expresion de apociii.

Country Status (10)

Country Link
US (1) US20240033280A1 (cg-RX-API-DMAC7.html)
EP (1) EP4221720A4 (cg-RX-API-DMAC7.html)
JP (1) JP7891470B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079394A (cg-RX-API-DMAC7.html)
CN (1) CN116348125A (cg-RX-API-DMAC7.html)
AU (1) AU2021353849A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004012A2 (cg-RX-API-DMAC7.html)
IL (1) IL300882A (cg-RX-API-DMAC7.html)
MX (1) MX2023003855A (cg-RX-API-DMAC7.html)
WO (1) WO2022072244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2023372971A1 (en) * 2022-11-02 2025-05-15 Ionis Pharmaceuticals, Inc. Methods for modulating complement factor b expression
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
KR20200123263A (ko) * 2013-02-14 2020-10-28 아이오니스 파마수티컬즈, 인코포레이티드 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
AU2016222548A1 (en) * 2015-02-27 2017-07-27 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein C-III (ApoCIII) expression in lipodystrophy populations
LT4119569T (lt) * 2015-11-06 2024-09-25 Ionis Pharmaceuticals, Inc. Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje

Also Published As

Publication number Publication date
JP7891470B2 (ja) 2026-07-16
BR112023004012A2 (pt) 2023-04-25
CN116348125A (zh) 2023-06-27
KR20230079394A (ko) 2023-06-07
AU2021353849A8 (en) 2023-03-30
IL300882A (en) 2023-04-01
AU2021353849A1 (en) 2023-03-23
US20240033280A1 (en) 2024-02-01
EP4221720A4 (en) 2024-11-13
EP4221720A1 (en) 2023-08-09
WO2022072244A1 (en) 2022-04-07
JP2023543898A (ja) 2023-10-18

Similar Documents

Publication Publication Date Title
AU2021353849A8 (en) Methods for reducing APOCIII expression
Braga et al. Clinical evidence for pharmaconutrition in major elective surgery
Henrotin et al. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations
Goldberg et al. Intra-articular hyaluronans: the treatment of knee pain in osteoarthritis
de Franciscis et al. Hyperhomocysteinaemia and chronic venous ulcers
BR112015025390A2 (pt) Composição, métodos para isolar célula tronco, para tratar um indivíduo e um paciente, para reduzir um depósito de gordura, para dissociar um tecido e uma matriz de proteína, para tratar ou curar uma cicatriz ou uma ferida, e para isolar células ilhotas, vetor de expressão, composição farmacêutica, formulação de liberação temporizada, e, kit
Jiang et al. Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells
Maltsev et al. Vitamin D and immunity
Bonifacio et al. Clinical outcome of long-term home parenteral nutrition in non-oncological patients: a report from two specialised centres
WO2022026092A3 (en) Method of treatment of neutrophil-driven inflammatory pathologies
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
Honda et al. Drug eruption following high-calorie infusion: a possible systemic type IV allergic reaction to sulphites
Özlü et al. Efficacy of a home exercise program on balance, kinesiophobia, pain and quality of life in post-COVID-19 patients
CN203107254U (zh) 一种棘突间动态稳定系统装置
Lin et al. Transfer of the superior portion of the pectoralis major flap for restoration of shoulder abduction
Mills The heart failure frequent flyer: an urban legend
AU2019100077A4 (en) Treatment for gastrointestinal diseases, depression, and anxieties
Lee et al. Home parenteral nutrition program and referral of potential candidates for intestinal and multivisceral transplantation in a single Brazilian center
Nygaard Otherworldly Beings in the Pre-Christian North: Tribal, Chiefdom, and Archaic Religion and the Use of Cultural Evolutionary Theory
Xianjin et al. Influence of wuqinxi on proprioceptive sensation and body balance function of female patients with knee osteoarthritis
Ivanets et al. Treatment of depression complicated by abuse and dependence on alcohol
In et al. Treatment with Vitis vinifera extract for controlling ascites and local swelling in snakebites
MU FELE
KARNIB The Effects of Caloric Vestibular Stimulation on Risk-Taking Propensity and Interoception in Healthy Participants
Badillo Botulinum toxin A